Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency

International Journal of Cancer

Volumn 133, Issue 3, 2013, Pages 757-765

  Vincent, Marie ^a   Bessard, Anne ^a   Cochonneau, Denis ^a   Teppaz, Géraldine ^a   Solé, Véronique ^a   Maillasson, Mike ^a   Birklé, Stéphane ^a   Garrigue Antar, Laure ^a   Quéméner, Agnès ^a   Jacques, Yannick ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

cancer therapy; GD2 disialoganglioside; immunocytokine; interleukin 15

Indexed keywords

ANTI GD2 RLI; ANTINEOPLASTIC AGENT; CYTOKINE; GANGLIOSIDE GD2; INTERLEUKIN 15; INTERLEUKIN 2; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG HALF LIFE; DRUG POTENCY; IMMUNOCOMPETENCE; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GANGLIOSIDES; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-15; INTERLEUKIN-15 RECEPTOR ALPHA SUBUNIT; LIVER NEOPLASMS; LYMPHOMA, T-CELL; MALE; MICE; MICE, INBRED A; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEUROBLASTOMA; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS;

EID: 84877964989     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28059     Document Type: Article

References (50)

1. Meazza R, Azzarone B, Orengo AM, et al. Role of common-γ chain cytokines in NK cell development and function: perspectives for immunotherapy. J Biomed Biotechnol 2011; 2011: 861920.
2. Carnemolla B, Borsi L, Balza E, et al. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 2002; 99: 1659-65.
3. Schwartz RN, Stover L, Dutcher J,. Managing toxicities of high-dose interleukin-2. Oncology (Williston Park, NY) 2002; 16: 11-20.
4. Halin C, Rondini S, Nilsson F, et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 2002; 20: 264-9.
5. Pasche N, Neri D,. Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 2012; 17: 583-90.
6. Kontermann RE,. Antibody-cytokine fusion proteins. Arch Biochem Biophys 2012; 526: 194-205.
7. Johannsen M, Spitaleri G, Curigliano G, et al. The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer 2010; 46: 2926-35.
8. Gilman AL, Ozkaynak MF, Matthay KK, et al. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. J Clin Oncol 2009; 27: 85-91.
9. Baluna R, Rizo J, Gordon BE, et al. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc Natl Acad Sci USA 1999; 96: 3957-62.
10. Munger W, DeJoy SQ, Jeyaseelan R, Sr, et al. Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell Immunol 1995; 165: 289-93.
11. Steel JC, Waldmann TA, Morris JC,. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci 2012; 33: 35-41.
12. Giri JG, Anderson DM, Kumaki S, et al. IL-15, a novel T cell growth factor that shares activities and receptor components with IL-2. J Leukoc Biol 1995; 57: 763-6.
13. Anderson DM, Kumaki S, Ahdieh M, et al. Functional characterization of the human interleukin-15 receptor α chain and close linkage of IL15RA and IL2RA genes. J Biol Chem 1995; 270: 29862-9.
14. Giri JG, Kumaki S, Ahdieh M, et al. Identification and cloning of a novel IL-15 binding protein that is structurally related to the α chain of the IL-2 receptor. EMBO J 1995; 14: 3654-63.
15. Marks-Konczalik J, Dubois S, Losi JM, et al. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci USA 2000; 97: 11445-50.
16. Waldmann TA, Dubois S, Tagaya Y,. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 2001; 14: 105-10.
17. Berger C, Berger M, Hackman RC, et al. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 2009; 114: 2417-26.
18. Kennedy MK, Glaccum M, Brown SN, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000; 191: 771-80.
19. Lodolce JP, Burkett PR, Boone DL, et al. T cell-independent interleukin 15Rα signals are required for bystander proliferation. J Exp Med 2001; 194: 1187-94.
20. Li XC, Demirci G, Ferrari-Lacraz S, et al. IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat Med 2001; 7: 114-18.
21. Dubois S, Mariner J, Waldmann TA, et al. IL-15Rα recycles and presents IL-15 in trans to neighboring cells. Immunity 2002; 17: 537-47.
22. Burkett PR, Koka R, Chien M, et al. Coordinate expression and trans presentation of interleukin (IL)-15Rα and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis. J Exp Med 2004; 200: 825-34.
23. Mortier E, Advincula R, Kim L, et al. Macrophage- and dendritic-cell-derived interleukin-15 receptor α supports homeostasis of distinct CD8+ T cell subsets. Immunity 2009; 31: 811-22.
24. Mortier E, Bernard J, Plet A, et al. Natural, proteolytic release of a soluble form of human IL-15 receptor α-chain that behaves as a specific, high affinity IL-15 antagonist. J Immunol 2004; 173: 1681-8.
25. Dubois S, Patel HJ, Zhang M, et al. Preassociation of IL-15 with IL-15R α-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44 high T cells and its antitumor action. J Immunol 2008; 180: 2099-106.
26. Epardaud M, Elpek KG, Rubinstein MP, et al. Interleukin-15/interleukin- 15R α complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res 2008; 68: 2972-83.
27. Stoklasek TA, Schluns KS, Lefrançois L,. Combined IL-15/IL-15Rα immunotherapy maximizes IL-15 activity in vivo. J Immunol 2006; 177: 6072-80.
28. Mortier E, Quéméner A, Vusio P, et al. Soluble interleukin-15 receptor α (IL-15R α)-sushi as a selective and potent agonist of IL-15 action through IL-15R β/γ. Hyperagonist IL-15 × IL-15R α fusion proteins. J Biol Chem 2006; 281: 1612-19.
29. Bouchaud G, Garrigue-Antar L, Solé V, et al. The exon-3-encoded domain of IL-15rα contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Rα. J Mol Biol 2008; 382: 1-12.
30. Huntington ND, Legrand N, Alves NL, et al. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med 2009; 206: 25-34.
31. Bessard A, Solé V, Bouchaud G, et al. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor α fusion protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther 2009; 8: 2736-45.
32. Cahan LD, Irie RF, Singh R, et al. Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2. Proc Natl Acad Sci USA 1982; 79: 7629-33.
33. Yuki N, Yamada M, Tagawa Y, et al. Pathogenesis of the neurotoxicity caused by anti-GD2 antibody therapy. J Neurol Sci 1997; 149: 127-30.
34. Svennerholm L, Boström K, Jungbjer B, et al. Membrane lipids of adult human brain: lipid composition of frontal and temporal lobe in subjects of age 20 to 100 years. J Neurochem 1994; 63: 1802-11.
35. Birklé S, Zeng G, Gao L, et al. Role of tumor-associated gangliosides in cancer progression. Biochimie 2003; 85: 455-63.
36. Mueller BM, Romerdahl CA, Gillies SD, et al. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol 1990; 144: 1382-6.
37. Imai M, Landen C, Ohta R, et al. Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res 2005; 65: 10562-8.
38. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15: 5323-37.
39. Handgretinger R, Anderson K, Lang P, et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 1995; 31: 261-7.
40. Alvarez-Rueda N, Leprieur S, Clémenceau B, et al. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen. Clin Cancer Res 2007; 13: 5613s-5620s.
41. Hori T, Uchiyama T, Tsudo M, et al. Establishment of an interleukin 2-dependent human T cell line from a patient with T cell chronic lymphocytic leukemia who is not infected with human T cell leukemia/lymphoma virus. Blood 1987; 70: 1069-72.
42. Nakamura Y, Russell SM, Mess SA, et al. Heterodimerization of the IL-2 receptor β- and γ-chain cytoplasmic domains is required for signalling. Nature 1994; 369: 330-3.
43. Perdreau H, Mortier E, Bouchaud G, et al. Different dynamics of IL-15R activation following IL-15 cis- or trans-presentation. Eur Cytokine Netw 2010; 21: 297-307.
44. Kendra K, Gan J, Ricci M, et al. Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice. Cancer Immunol Immunother 1999; 48: 219-29.
45. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6: 443-6.
46. Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, et al. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res 2003; 9: 5866-73.
47. Bruhns P,. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012; 119: 5640-9.
48. Eisenman J, Ahdieh M, Beers C, et al. Interleukin-15 interactions with interleukin-15 receptor complexes: characterization and species specificity. Cytokine 2002; 20: 121-9.
49. Rowley J, Monie A, Hung C-F, et al. Inhibition of tumor growth by NK1.1+ cells and CD8+ T cells activated by IL-15 through receptor β/common γ signaling in trans. J Immunol 2008; 181: 8237-47.
50. Kermer V, Baum V, Hornig N, et al. An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site. Mol Cancer Ther 2012; 11: 1279-88.